According to the World Health Organization (WHO), major depressive disorder (MDD) is the most common mental health disorder worldwide. MDD is a chronic and devastating disorder that has a lifetime prevalence of ~14% in the United States and results in poor personal, social, and vocational outcomes if left untreated. Furthermore, the economic burden of MDD in the United States exceeded $210 billion in 2010, which includes medical treatment, workplace-related costs, and suicide-related costs. Patients suffering from MDD have a number of pharmacological treatment options, including both “typical” and “atypical” antidepressant drugs. The typical antidepressants category comprises four different drug classes: (1) monoamine oxidase inhibitors (MAOI), (2) tricyclic antidepressants (TCA), (3) selective-serotonin reuptake inhibitors (SSRI), and (4) serotonin-norepinephrine reuptake inhibitors (SNRI). All of these drugs ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles